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and p2PSA-related indices on pathological reclassification 
at 1 year after beginning AS were investigated.
Results The pathological reclassification rate was 37.3 %. 
According to the univariate analysis, prostate volume 
(p = 0.049), number of biopsy cores (p = 0.047), per-
centage of positive biopsy cores (p = 0.023), p2PSA to 
free PSA ratio (%p2PSA) (p = 0.003) and prostate health 
index (phi) (p = 0.010) at baseline were significantly dif-
ferent between the reclassification and non-reclassifica-
tion groups. By multivariate logistic regression analysis, 
baseline %p2PSA (p = 0.008) and phi (p = 0.008) were 
the only independent predictive factors for pathological 
upgrade at 1 year after AS commencement.
Conclusions Baseline %p2PSA and phi may predict the 
pathological reclassification at 1 year after starting AS, 
which could be due to the under detection of clinically sig-
nificant prostate cancer at AS enrollment.
Keywords [−2]proPSA · Active surveillance · 
Japanese cohort · Low-risk prostate cancer · Pathological 
reclassification
Introduction
PSA-based screening was found to benefit survival in 
males ages 50 to 69 in the European Randomized Study 
of Screening for Prostate Cancer (ERSPC) (Schroder et al. 
2012) and the Goteborg prospective randomized study 
(Hugosson et al. 2010). This study further demonstrated 
that one male per 1,055 screened, primarily at 4-year inter-
vals (Schroder et al. 2012), and one male per 293 screened 
at 2-year intervals (Hugosson et al. 2010) would not suffer 
prostate cancer-related death over a decade. To avert pros-
tate cancer over a lifetime, however, the survival benefit 
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aggressiveness may be evaluated more accurately. The 
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must be much greater. Issues of over-detection and subse-
quent overtreatment have emerged as serious drawbacks of 
PSA-based screening. Updated ERSPC data assumed that 
37 radical treatments were required to prevent one death 
from prostate cancer (Schroder et al. 2012). Any radi-
cal treatment has a risk of decreasing QOL, thus AS may 
have an important role in decreasing the frequency of over-
treatments throughout life. Candidates for AS are usually 
selected according to pretreatment pathological features 
of prostate biopsies and initial PSA values. Previous retro-
spective studies have demonstrated that a substantial num-
ber of patients who qualified for AS but underwent imme-
diate radical prostatectomy (RP) were upgraded by the 
results of whole-prostate specimens (Behbahani et al. 2012; 
Iremashvili et al. 2012). Since 20–30 % of the initial biopsy 
underestimation is unavoidable, most AS protocols include 
strict PSA kinetics monitoring. Conversely, unreliable PSA 
and PSA kinetics readings during AS have been reported 
(Sugimoto et al. 2010; Ross et al. 2010; NCCN guidelines 
TM version 2013). Therefore, periodic repeat biopsies for 
patients with intermediate PSA doubling time (PSADT) are 
recommended for detection of aggressive tumors during 
AS. Such precautions may help to avoid delaying radical 
treatment.
To compensate for the unreliability of PSA, PSA 
kinetics or prostate biopsies, proPSA (Peter et al. 2001; 
Mikolajczyk et al. 2001) may be a new candidate bio-
marker employable at enrollment or AS monitoring, as 
p2PSA-related indices have high specificity not only for 
prostate cancer but also for other high-grade and high-
volume tumors (Jansen et al. 2010; Catalona et al. 2011; 
Ito et al. 2012; Guazzoni et al. 2012). The aim of the pre-
sent retrospective study was to evaluate the predictive 
significance of p2PSA-related indices on the likelihood 
of pathological reclassification at the 1 year protocol 
biopsy during AS in the Japanese multicenter prospective 
AS cohort.
Materials and methods
Seven cancer center hospitals and six university hospi-
tals in Japan participated in the multicenter prospective 
one-arm cohort study of AS. The institutional review 
board of each participating institution approved the study 
protocol. Participants in the AS study were subject to 
the following inclusion criteria: (1) stage T1cN0M0 (2) 
age 50–80 (3) serum PSA ≤ 20 ng/ml (4) 1 or 2 posi-
tive cores per 6–12 systematic biopsy cores (5) Gleason 
score (GS) ≤6 and (6) maximum cancer involvement in 
positive cores of ≤50 %. All biopsy specimens at entry 
and during AS were diagnosed by one central urologic 
pathologist (T.S.).
Between January 2002 and December 2003, 134 patients 
who met the inclusion criteria were registered after pro-
viding written informed consent. Of the 134 patients, 118 
(88.1 %) actually proceeded to AS, while the remaining 
16 patients preferred to undergo immediate radical treat-
ments. Patients who opted for the AS program had PSA 
measurements every 2 months for the initial 6 months, with 
follow-ups every 3 months thereafter. Serum samples were 
collected and stored at −80 °C at each PSA measurement, 
according to the study protocol. Prostate biopsy was rec-
ommended for patients who remained on AS for 1 year. 
PSADT shorter than 2 years, or pathological reclassifica-
tion (GS 7 or greater, more than two positive biopsy cores 
or more than 50 % cancer involvement of any biopsy core) 
upon the 1 year prostate biopsy was trigger for curative 
intervention.
One year after participating in the AS study, 15 (12.7 %) 
patients discontinued AS. Elimination reasons were 
PSADT <2 years for seven patients, patient preference 
for five patients, one patient underwent RP due to difficult 
voiding, one patient transferred to another hospital, and one 
patient was lost during follow-up. Of the remaining 103 
patients who continued AS, 67 (65.0 %) patients underwent 
repeat biopsy and 36 (35.0 %) did not at 1 year after com-
mencing AS.
Total PSA, free PSA and p2PSA were measured in 
serum samples collected upon entry into the study using the 
UniCel DxI800 Immunoassay System analyzer (Beckman 
Coulter Inc., Brea, CA, USA). Hybritech calibrators (Beck-
man Coulter Inc., Brea, CA, USA) were used for total PSA 
and free PSA assays. Various clinicopathological features 
upon AS entry and baseline free to total PSA ratio (%free 
PSA) (base model), %p2PSA and phi (extended model) 
Table 1  Result of repeat biopsy at 1 year after entering the AS study
% of maximum cancer involvement; occupancy of maximum can-
cer length (mm)/total core length (mm) in positive biopsy speci-
men × 100 (%)
No. of patients (%)
Reclassification 25 (37.3)
 Only no. of positive cores >2 10 (14.9)
 Only Gleason score (GS) >6 4 (6.0)
 Only  % of maximum cancer  
involvement ≥50 %
1 (1.5)
 GS >6 and no. of positive cores >2 3 (4.5)
 GS >6 and  % of maximum  
cancer involvement ≥50 %
2 (3.0)
 GS >6, no. of positive cores  




No cancer 23 (34.3)
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were investigated in terms of their predictive value for pros-
tate biopsy pathological reclassification. Phi was calculated 
using the following formula: (p2PSA/free PSA) × √total 
PSA.
All statistical analyses were performed using the SPSS 
ver. 20.0 (SPSS) or Stat Flex ver. 6.0 software package. 
Significance was calculated using the Mann-Whitney U 
test for continuous variables and the chi-square test for 
categorical variables. A p value of <0.05 was considered 
to indicate statistical significance. Cutoffs of the above 
clinicopathological factors for multivariable analyses were 
explored by separating patients into binary, tertiary, quar-
tiles or quintiles in order to establish more significant and 
meticulous separation. If two adjacent subgroups were 
considered to have an equal predictive value, they were 
combined.
A stepwise multiple logistic regression analysis was 
used to determine independent significant predictive 
factors, in which all clinicopathological factors were han-
dled as categorical variables.
Results
The median age of the 67 patients at the time of enroll-
ment was 70 years (ranging from 55 to 79). Pathological 
reclassification 1 year after beginning AS was identified 
in 37.3 % (25/67) patients. The reasons for pathological 
reclassification in 25 of the patients are shown in Table 1. 
Among these 25 patients, 15 (60.0 %) had only one 
upgrading factor and 10 (40.0 %) had any combination of 
two or three upgrading factors. Table 2 displays compari-
sons of the baseline clinicopathological features of males 
with or without pathological reclassification. Prostate vol-
ume (p = 0.049), biopsy core number (p = 0.047) and the 
percentage of positive cores (p = 0.023) at baseline were 
Table 2  Differences in the 
baseline clinicopathological 
features between the 
reclassification and non-
reclassification groups
% of maximum cancer 
involvement; occupancy of 
maximum cancer length (mm)/
total core length (mm) in 
positive biopsy specimen × 100 
(%)
* Mann-Whitney U test,  
** Chi-square test
Reclassification group  
(n = 25)




 Median (range) 69 (60–78) 70 (55–79) 0.682*
 Mean ± SD 69.48 ± 4.80 69.57 ± 4.96
Prostate volume (cc)
 Median (range) 31.3 (8–102.8) 40.3 (15–97.8) 0.049*
 Mean ± SD 41.08 ± 19.34 43.99 ± 18.89
Total PSA (ng/ml)
 Median (range) 6.4 (3.9–17.0) 6.05 (2.9–13.0) 0.831*
 Mean ± SD 7.31 ± 3.58 6.92 ± 2.80
PSAD (ng/ml/cc)
 Median (range) 0.18 (0.9–0.84) 0.15 (0.06–0.50) 0.089*
 Mean ± SD 0.25 ± 0.20 0.18 ± 0.11
Gleason score
 5 (%) 3 (12.0 %) 5 (11.9 %) 1.000**
 6 (%) 22 (88.0 %) 37 (88.1 %)
No. of positive cores
 1 (%) 16 (64.0 %) 35 (83.3 %) 0.073**
 2 (%) 9 (34.0 %) 7 (16.7 %)
No. of biopsy core taken
 6–8 (%) 19 (76.0 %) 22 (52.4 %) 0.047**
 9–12 (%) 6 (24.0 %) 20 (47.6 %)
% of positive cores
 Median (range) 16.7 (8.3–33.3) 12.5 (8.3–33.3) 0.023*
 Mean ± SD 17.70 ± 7.65 14.09 ± 6.66
 10.0 or less (%) 4 (16.0 %) 16 (38.1 %) 0.048**
 Greater than 10.0 (%) 21 (84.0 %) 26 (61.9 %)
% of maximum cancer involvement (%)
 Median (range) 10 (3.6–30) 11.75 (2.1–42.9) 0.943*
 Mean ± SD 14.02 ± 9.11 13.67 ± 8.88
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significantly different between the reclassification and non-
reclassification groups, while other parameters did not dif-
fer significantly.
Table 3 shows comparisons of baseline %free PSA, 
%p2PSA and phi between the reclassification and non-
reclassification groups. Baseline %free PSA, %p2PSA 
and phi were handled as both continuous and categorical 
variables. There were no significant differences in %free 
PSA between the two groups when used as continuous 
(p = 0.805) or categorical (p = 0.462) variables. Con-
versely, %p2PSA and phi in the reclassification group were 
significantly higher than those in the non-reclassification 
group when used as continuous or categorical variables 
(%p2PSA, p = 0.003 and p = 0.013, respectively; phi, 
p = 0.010 and p = 0.007, respectively).
Table 4 shows the results of multivariate logistic regres-
sion analyses using a base model that included age, pros-
tate volume, percentage of positive biopsy core, maximum 
cancer involvement and %free PSA. Only prostate volume 
was a significant predictive factor for pathological reclassi-
fication at 1 year following AS in the base model. However, 
if p2PSA-related indices were included in the base model, 
%p2PSA (p = 0.008) and phi (p = 0.008) were the only 
independent predictive factors for pathological reclassifica-
tion at 1 year after entering the AS study. Figure 1a shows 
that the biopsy reclassification rate increased with %p2PSA 
levels. The biopsy reclassification percentage at 1 year 
increased from 15.38 % in the lowest group (%p2PSA 
1.51 % or less) to 69.23 % in the highest group (%p2PSA 
greater than 2.93 %). The biopsy reclassification rate also 
increased with phi levels (Fig. 1b). These results demon-
strate a strong correlation of baseline %p2PSA and phi 
with the likelihood of pathological reclassification at 1 year 
after beginning AS.
Discussion
In the present study, there was a significant association of 
baseline %p2PSA and phi with pathological reclassifica-
tion at a 1 year repeat biopsy. These results suggest that 
p2PSA-related parameters at diagnosis may be predictive 
of an underestimation of clinically significant prostate can-
cer at AS enrollment.
Some studies have shown the usefulness of proPSA-
related parameters in prostate cancer detection. Jansen 
et al. reported that phi had a higher AUC for prostate can-
cer detection than either total PSA or %free PSA in two 
European populations (Jansen et al. 2010). Catalona et al. 
similarly reported that the AUC for phi was higher than 
Table 3  Differences in the PSA-related indices between the reclassification and non-reclassification groups
* Mann-Whitney U test, ** Chi-square test
Reclassification group (n = 25) Non-reclassification group (n = 42) p value
%free PSA
 Median (range) 15.96 (4.55–39.67) 14.70 (5.86–31.68) 0.805*
 Mean ± SD 16.67 ± 7.62 16.15 ± 6.86
 15.96 or less (%) 12 (48.0 %) 22 (52.4 %) 0.462**
 >15.96 (%) 13 (52.0 %) 20 (47.6 %)
%p2PSA
 Median (range) 2.44 (1.13–6.21) 1.88 (0.78–6.63) 0.003*
 Mean ± SD 2.75 ± 1.20 2.11 ± 1.12
 1.51 or less (%) 2 (8.0 %) 11 (26.2 %) 0.013** (−1.51 vs. 1.51–2.25 vs. 
2.25–2.93 vs. 2.93–)
 1.51 to 2.25 (%) 7 (28.0 %) 20 (47.6 %) 0.008** (−1.15 vs. 1.15–2.25 vs. 2.25−)
 2.25 to 2.93 (%) 7 (28.0 %) 7 (16.7 %) 0.014** (−1.15 vs. 1.15–2.93 vs. 2.93−)
 >2.93 (%) 9 (36.0 %) 4 (9.5 %) 0.006** (−2.25 vs. 2.25–2.93 vs. 2.93−)
0.063** (−1.51 vs. 1.51−)
0.003** (−2.25 vs. 2.25−)
0.011** (−2.93 vs. 2.93−)
Phi
 Median (range) 60.3 (32.9–141.3) 47.8 (23.8–199.6) 0.010*
 Mean ± SD 72.4 ± 31.3 55.7 ± 31.5
 43.2 or less (%) 3 (12.0 %) 14 (33.3 %) 0.007** (−43.2 vs. 43.2–76.3 vs. 76.3–)
 43.2 to 76.3 (%) 11 (44.0 %) 23 (54.8 %) 0.046** (−43.2 vs. 43.2–)
 >76.3 (%) 11 (44.0 %) 5 (11.9 %) 0.004** (−76.3 vs. 76.3–)
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those of total PSA or %fPSA in a multicenter study that 
included 892 males. They demonstrated that males with phi 
55.0 or higher had a 4.7-fold greater risk of prostate can-
cer compared to those with a phi of less than 25.0 (Cat-
alona et al. 2011). They further showed that the use of phi 
could prevent 28 and 33 % of unnecessary biopsies while 
maintaining 95 and 90 % sensitivity, respectively. Moreo-
ver, Ito et al. recently demonstrated a very high specific-
ity of prostate volume-adjusted p2PSA-related indices at a 
sensitivity of 90 % in a Japanese cohort (Ito et al. 2012). 
With respect to the relationships between grade and cancer 
volume and p2PSA-related parameters, Ito et al. also dem-
onstrated significant relationships between the level of phi 
and prostate volume-adjusted p2PSA-related indices with 
GS and cancer occupancy in biopsy specimens. Further-
more, Guazzoni et al. reported that %p2PSA and phi sig-
nificantly discriminated males with pT3 disease, pathologic 
Gleason sum ≥7 and Gleason sum upgrading based on RP 
specimens (Guazzoni et al. 2012).
Regarding the predictive power during AS of p2PSA 
and p2PSA-related parameters for reclassification at repeat 
biopsy, Tosoian and colleagues recently reported that 
p2PSA and p2PSA-related parameters were predictive of 
reclassification in very low-risk patients who underwent AS 
(Tosoian et al. 2012). They showed that baseline and longi-
tudinal changes in the %free PSA, %p2PSA, p2PSA/%free 
PSA and phi values were associated with reclassification 
at repeat biopsies. These results are comparable to those 
obtained in the present study despite the different ethnici-
ties examined (primarily Caucasians versus Asians). The 
inclusion criteria in both cohorts were similar, but ours 
were less stringent, in that initial PSA could be up to 20 ng/
ml and there was no restriction on PSA density. The pre-
sent study focused on the likelihood of reclassification at 
a 1 year repeat biopsy while Tosoian et al. assessed reclas-
sification during relatively long-term follow-up (a median 
of 4.3 years).
Most reclassifications at a 1 year repeat biopsy may 
not be due to disease progression, but to underestimation 
at initial biopsy. Our results demonstrate the high diagnos-
tic ability of p2PSA-related parameters for discriminat-
ing candidates for AS with non-significant prostate cancer 
from those with significant cancer. Classic clinicopatho-
logical factors, including prostate volume, which were 
significantly predictive of biopsy reclassification by the 
base model, became less significant when %p2PSA or phi 
was analyzed by multivariate logistic regression. Thus, 
%p2PSA and phi could be independent significant factors 
when divided into quartiles and quintiles, respectively. This 
suggests that %p2PSA and phi are useful markers. Use of 
these markers may reduce the incidence of underestima-
tion at initial diagnosis, enabling more accurate selection of 
suitable candidates for AS.
This retrospective study had several limitations. First, a 
median of eight biopsy cores were obtained (range, 6–12), 
which is relatively few compared to contemporary practice. 
Most Japanese institutions performed eight-core biopsies 
during the study period. Therefore, the relatively high reclas-
sification ratio in the present study may be due to the fewer 
biopsy cores taken. The likelihood of pathological reclassi-
fication was significantly higher in patients from whom 6 to 
8 biopsy cores were taken, compared to those from whom 
9 to 12 cores were taken at study entry (Chi-square test 
p = 0.047). This suggests that an immediate second repeat 
Table 4  Multivariate analyses using base model and extended model including  %p2PSA or phi on the base model
odds ratio (95 % confidence interval)/p value
Age (years): 70 or less (0), greater than 70 (1)
Prostate volume (cc): 47.0 or less (1), greater than 47.0 (0)
Percentage of positive cores (%): 10.0 or less (0), greater than 10.0 (1)
Maximum cancer involvement (mm) 11.5 or less (0), greater than 11.5 (1)
%free PSA: 15.96 or less (1), greater than 15.96 (0)
%p2PSA: 1.51 or less (0), 1.51–2.25 (1), 2.25–2.93 (2), greater than 2.93 (3)
Phi: 43.2 or less (0), 43.2–76.3 (1), greater than 76.3 (2)
% of maximum cancer involvement; occupancy of maximum cancer length (mm)/total core length (mm) in positive biopsy specimen × 100 (%)
Base model Base model + %p2PSA Base model + phi
Age 0.465 (0.148–1.462)/0.190 0.480 (0.145–1.591)/0.231 0.420 (0.124–1.423)/0.164
Prostate volume 4.304 (1.121–16.522)/0.033 2.859 (0.681–12.004)/0.151 3.235 (0.767–13.641)/0.110
% of positive cores 2.747 (0.751–10.044)/0.127 3.539 (0.809–15.476)/0.093 3.264 (0.757–14.071)/0.113
% of maximum cancer involvement 0.954 (0.320–2.851)/0.933 0.962 (0.299–3.097)/0.948 1.026 (0.318–3.310)/0.966
%free PSA 0.604 (0.192–1.904)/0.390 0.468 (0.134–1.632)/0.234 0.384 (0.105–1.401)/0.147
%p2PSA – 2.356 (1.252–4.435)/0.008 –
Phi – – 3.650 (1.408–9.461)/0.008
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multiple-core biopsy should be performed prior to AS enroll-
ment to judge candidates based on eight or fewer biopsy 
cores. Second, we enrolled patients with a relatively high ini-
tial PSA level (10–20 ng/ml). However, there was no signifi-
cant difference in total PSA between the reclassification and 
non-reclassification groups. Furthermore, there was no sig-
nificant difference in reclassification rates between patients 
with PSA ≤ 10 ng/ml and those with PSA in the reflex range 
of 10–20 ng/ml. Including PSA values of 10–20 ng/ml may 
thus not affect the core results of the present study. Finally, 
the acceptance rates of repeat biopsies were low, at 65.0 %. 
However, there were no significant differences in the base-
line clinicopathological findings among the following three 
groups: 67 patients that underwent repeat biopsy, 36 patients 
that refused repeat biopsy and 15 patients that discontinued 
AS within 1 year (data not shown).
In conclusion, baseline %p2PSA and phi were the only 
independent factors predictive of the likelihood of pathological 
reclassification at 1 year after AS commencement. This may 
be due to the under detection of clinically significant prostate 
cancer at the time of AS enrollment. However, baseline total 
PSA, %free PSA and classical clinicopathological findings 
were not significantly associated with biopsy reclassification. 
Parameters including p2PSA might be promising and supple-
mental biomarkers of tumor aggressiveness and burden. These 
p2PSA-related indices may enhance the safety of the AS pro-
gram. In the future, longitudinal p2PSA-related indices moni-
toring during AS will be valuable.
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